On the morning of the 20th, employees are working on AstraZeneca vaccine packaging at the SK Bioscience plant in Andong, Gyeongbuk. yunhap news
The amount of vaccine supply for the novel coronavirus infection (Corona 19) in Europe is showing signs of a vaccine crisis, as governments have announced a lawsuit against vaccine manufacturers. The Korean government is in the position that “there is no problem with the domestic vaccine supply and demand plan.”
The Centers for Disease Control and Prevention said on the 24th, “Korea will receive AstraZeneca vaccine produced by SK Bioscience from the first quarter. There is no change in the supply plan so far.”
In Europe, the supply of AstraZeneca vaccine has been delayed following Pfizer. Italy foretold legal action, saying that Pfizer and AstraZeneca could not supply the promised quantity on time. The government expects that there will be no disruption in the vaccine supply plan because Korea receives domestically produced vaccines even in such foreign conditions. Currently, two kinds of vaccines from overseas pharmaceutical companies are being commissioned in Korea. SK Bioscience is producing AstraZeneca vaccine and NovaVax vaccine.
The vaccine supply clock in Korea is expected to return from next week. In early February, 50,000 Pfizer vaccines will be delivered first through Cobax Facility (multi-national vaccine joint purchase method). The vaccine received in this way is expected to be vaccinated by first-line medical staff who care for corona19 patients before the Lunar New Year holidays. Then, in mid-February, 750,000 AstraZeneca vaccines produced in Korea will be released first. 566,000 elderly people living in group facilities such as nursing homes are the top targets for vaccination. AstraZeneca vaccine will be released sequentially for a total of 10 million people.
President Moon Jae-in visits SK Biosciences in Andong City, Gyeongbuk on the morning of the 20th, tours the COVID-19 vaccine production facility, and listens to the explanation of plant manager Lee Sang-gyun. On the left is SK Chairman Choi Tae-won. SK Biosciences is consigning production of AstraZeneca, a corona19 vaccine that will be introduced in Korea. 2021.01.20./Cheongwadae Photo Reporter = Kyunghyang Shinmun Kang Yun-joong reporter
20 million people for Modena and 6 million Janssen will enter the second quarter, and 10 million Pfizer will enter the third quarter. NovaVax vaccine will also secure 20 million domestic vaccines through a technology introduction contract with SK Bioscience. A total of 10 million vaccines were pre-purchased through CoVax, but this amount was not confirmed when and what kind of vaccine will be available in addition to the initial amount (for Pfizer 50,000).
The government will announce the COVID-19 vaccination implementation plan on the afternoon of the 28th, which includes the current status of the vaccine introduction, priority vaccination targets, vaccination timing by vaccination target, and preparation status. Through this, the goal is to form group immunity before the next winter after 70% of the people excluding children and adolescents complete vaccination in November.
Reporter Esther [email protected]